Innoviva

Q4 2025 -2.73%Q3 2025 +13.12%Q2 2025 +1.04%Q1 2025 -0.91%Q4 2024 -1.96%Q3 2024 +2.93%Q2 2024 +1.58%Q1 2024 -1.55%Q4 2023 -0.72%Q3 2023 +7.01%Q2 2023 -1.35%Q1 2023 +4.45%Q4 2022 -5.17%Q3 2022 +5.06%Q2 2022 -1.73%Q1 2022 +0.93%Q4 2021 +13.71%Q3 2021 +8.80%Q2 2021 +6.33%Q1 2021 +0.86%Q4 2020 +0.97%Q3 2020 +11.32%Q2 2020 +0.44%Q1 2020 +5.27%Q4 2019 +3.50%Q3 2019 +6.22%Q2 2019 -15.08%Q1 2019 +6.49%Q4 2018 -3.31%Q3 2018 +2.28%Q2 2018 -1.22%Q1 2018 -2.87%Q4 2017 +8.51%Q3 2017 -11.88%Q2 2017 +4.35%Q1 2017 -8.29%Q4 2016 +1.74%Q3 2016 -1.64%Q2 2016 +9.16%Q1 2016 -1.04%Q4 2015 +14.55%Q3 2015 +1.15%Q2 2015 -10.82%Q1 2015 -6.27%Q4 2014 +10.84%Q3 2014 -5.01%Q2 2014 +4.52%Q1 2014 -1.10%Q4 2013 -2.08%Q3 2013 +8.29%Q2 2013 -3.68%Q1 2013 +11.33%Q4 2012 -4.92%Q3 2012 -9.42%Q2 2012 -7.07%Q1 2011 -1.87%Q1 2012 +19.44%Q4 2011 +0.77%Q3 2011 +8.64%Q2 2011 +1.35%Q4 2010 -1.05%Q3 2010 +2.74%Q2 2010 +7.98%Q1 2010 -9.20%

May 08, 2024

•

Mar 31, 2024

Innoviva Q1 2024 Earnings Report

Reported strong first quarter performance driven by resilient cash flows and robust revenue growth.

Key Takeaways

Innoviva reported a strong first quarter with a focus on its core GSK royalties portfolio and revenue growth across its commercial products. The company is focused on driving shareholder value through cost discipline, strategic investments, and share buybacks.

Core royalty platform is on track, receiving GSK royalties of $61.9 million.

Net product revenues reached $19.1 million, a 66% year-over-year increase, driven by XACDURO® launch and GIAPREZA® growth.

Positive Phase 3 zoliflodacin clinical trial results for uncomplicated gonorrhea were highlighted at ESCMID Global 2024, with NDA submission expected in early 2025.

Derek Small was appointed to the Company’s Board of Directors.

Total Revenue

$81M

Previous year: $76.4M